Xintela AB (publ)
XINT
Rank in Stocks
#28110
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden,... Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Share Price
$0.01428366
Last synced: 2026-11-09
Market Cap
$12.30M
Change (1 day)
3.13%
Change (1 year)
-50.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xintela AB (publ) (XINT)
Category
Healthcare
EPS for Xintela AB (publ) (XINT)
EPS as of June 2026 TTM: $-0.01
According to Xintela AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.01, equal to its 2024 EPS of $-0.01.
EPS history for Xintela AB (publ) from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | -41.00% |
| 2025 | $-0.01 | 22.58% |
| 2024 | $-0.01 | -51.94% |
| 2023 | $-0.01 | -63.66% |
| 2022 | $-0.04 | -23.49% |
| 2021 | $-0.05 | -40.05% |
| 2020 | $-0.08 | 18.53% |
| 2019 | $-0.07 | 26.80% |
| 2018 | $-0.05 | -6.36% |
| 2017 | $-0.06 | 16.28% |
| 2016 | $-0.05 | 2.38% |
| 2015 | $-0.05 | 288.24% |
| 2014 | $-0.01 | -0.83% |
| 2013 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -265,523.73% |
US
|
|
| $-7.07 | 119,730.51% |
US
|
|
| $-5.29 | 89,561.02% |
AU
|
|
| $12.88 | -218,406.78% |
BE
|
|
| $21.56 | -365,523.73% |
NL
|
Questions about Xintela AB (publ)'s earnings per share (EPS)
What is Xintela AB (publ)'s earnings per share (EPS)?
Xintela AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was Xintela AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Xintela AB (publ)'s earnings per share (EPS) was $-0.01, compared with $-0.01 in 2024.
How has Xintela AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Xintela AB (publ)'s earnings per share (EPS) was highest in 2025 ($-0.01) and lowest in 2020 ($-0.08).
How does Xintela AB (publ)'s earnings per share (EPS) compare with similar companies?
Xintela AB (publ)'s earnings per share (EPS) ($-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.